Atorvastatin (hemicalcium trihydrate)

Atorvastatin hemicalcium trihydrate is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium trihydrate inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].

Product Specifications

CAS Number

[344920-08-7]

UNSPSC

12352005

Target

Autophagy; HMG-CoA Reductase (HMGCR)

Type

Reference compound

Related Pathways

Autophagy; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/atorvastatin-hemicalcium-trihydrate.html

Purity

99.70

Solubility

10 mM in DMSO

Smiles

O=C(C(C(C1=CC=CC=C1)=C(C2=CC=C(F)C=C2)N3CC[C@@H](O)C[C@@H](O)CC(O)=O)=C3C(C)C)NC4=CC=CC=C4.[1/2].[Ca].O.O.O

Molecular Formula

C33H35FN2O5.1/2Ca.3H2O

Molecular Weight

632.73

References & Citations

[1]Santodomingo-Garzón T, et al. Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol. 2006 Sep;149 (1) :14-22.|[2]Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50 (4) :458-61.|[3]Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15 (5) : p. 678-82.|[4]Song XJ, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8 (7) :564-72.|[5]Li Y, et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One. 2017 Apr 3;12 (4) :e0174821.